Giraldina Trevejo-Nunez, MD, has been awarded funding in the amount of $156,500 for a two-year grant by the National Institutes of Health/National Heart Lung, and Blood Institute (NIH/NHLBI) entitled “Domain-specific role of IL-17RA in controlling Klebsiella pneumoniae lung infection”. This proposal was submitted in response to the limited competition funding opportunity entitled Small Research Grant Program for NHLBI K01/K08/K23 Recipients (R03) under funding opportunity number RFA-HL-20-029.

Klebsiella pneumoniae (KP) represents the third leading cause of health-care associated pneumonia and it challenges the medical community due to its multidrug resistance profile causing significant morbidity and mortality particularly in immunosuppressed patients. IL-17 is an essential mediator of immunity to KP and animal models with IL-17 receptor (IL-17R) deficiency are susceptible to KP pneumonia. The mechanisms by which IL-17 and its receptor IL-17R mediate specific downstream signals in KP pneumonia are not fully elucidated. The preliminary data revealed that the distal domain of IL-17RA, also known as CBAD, is indispensable to control this infection. This proposal will determine the immune and molecular mechanisms by which the IL-17RA CBAD domain constrains KP pneumonia. Understanding the molecular mechanisms of the lung to control KP will give us insight to better control this infection.

Please join us in congratulating Giraldina!